1
|
Navas F, Chocarro-Calvo A, Iglesias-Hernández P, Fernández-García P, Morales V, García-Martínez JM, Sanz R, De la Vieja A, García-Jiménez C, García-Muñoz RA. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions. J Med Chem 2024; 67:6410-6424. [PMID: 38592014 PMCID: PMC11056991 DOI: 10.1021/acs.jmedchem.3c02393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 03/15/2024] [Accepted: 03/27/2024] [Indexed: 04/10/2024]
Abstract
We report two novel prodrug Pt(IV) complexes with bis-organosilane ligands in axial positions: cis-dichloro(diamine)-trans-[3-(triethoxysilyl)propylcarbamate]platinum(IV) (Pt(IV)-biSi-1) and cis-dichloro(diisopropylamine)-trans-[3-(triethoxysilyl) propyl carbamate]platinum(IV) (Pt(IV)-biSi-2). Pt(IV)-biSi-2 demonstrated enhanced in vitro cytotoxicity against colon cancer cells (HCT 116 and HT-29) compared with cisplatin and Pt(IV)-biSi-1. Notably, Pt(IV)-biSi-2 exhibited higher cytotoxicity toward cancer cells and lower toxicity on nontumorigenic intestinal cells (HIEC6). In preclinical mouse models of colorectal cancer, Pt(IV)-biSi-2 outperformed cisplatin in reducing tumor growth at lower concentrations, with reduced side effects. Mechanistically, Pt(IV)-biSi-2 induced permanent DNA damage independent of p53 levels. DNA damage such as double-strand breaks marked by histone gH2Ax was permanent after treatment with Pt(IV)-biSi-2, in contrast to cisplatin's transient effects. Pt(IV)-biSi-2's faster reduction to Pt(II) species upon exposure to biological reductants supports its superior biological response. These findings unveil a novel strategy for designing Pt(IV) anticancer prodrugs with enhanced activity and specificity, offering therapeutic opportunities beyond conventional Pt drugs.
Collapse
Affiliation(s)
- Francisco Navas
- Group
of Chemical and Environmental Engineering, Rey Juan Carlos University. C/Tulipán s/n, Móstoles, Madrid28933, Spain
| | - Ana Chocarro-Calvo
- Department
of Basic Health Sciences. Rey Juan Carlos
University. Avda. Atenas
s/n, Alcorcón, Madrid 28922, Spain
| | - Patricia Iglesias-Hernández
- Endocrine
Tumor Unit Chronic Disease Program (UFIEC). Carlos III Health Institute. Ctra. Majadahonda a Pozuelo km 2,2. Majadahonda, Madrid 28220, Spain
| | - Paloma Fernández-García
- Group
of Chemical and Environmental Engineering, Rey Juan Carlos University. C/Tulipán s/n, Móstoles, Madrid28933, Spain
| | - Victoria Morales
- Group
of Chemical and Environmental Engineering, Rey Juan Carlos University. C/Tulipán s/n, Móstoles, Madrid28933, Spain
| | - José Manuel García-Martínez
- Department
of Basic Health Sciences. Rey Juan Carlos
University. Avda. Atenas
s/n, Alcorcón, Madrid 28922, Spain
| | - Raúl Sanz
- Group
of Chemical and Environmental Engineering, Rey Juan Carlos University. C/Tulipán s/n, Móstoles, Madrid28933, Spain
| | - Antonio De la Vieja
- Endocrine
Tumor Unit Chronic Disease Program (UFIEC). Carlos III Health Institute. Ctra. Majadahonda a Pozuelo km 2,2. Majadahonda, Madrid 28220, Spain
| | - Custodia García-Jiménez
- Department
of Basic Health Sciences. Rey Juan Carlos
University. Avda. Atenas
s/n, Alcorcón, Madrid 28922, Spain
| | - Rafael A. García-Muñoz
- Group
of Chemical and Environmental Engineering, Rey Juan Carlos University. C/Tulipán s/n, Móstoles, Madrid28933, Spain
| |
Collapse
|
2
|
Liu C, Wu K, Li J, Mu X, Gao H, Xu X. Nanoparticle-mediated therapeutic management in cholangiocarcinoma drug targeting: Current progress and future prospects. Biomed Pharmacother 2023; 158:114135. [PMID: 36535198 DOI: 10.1016/j.biopha.2022.114135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Revised: 12/09/2022] [Accepted: 12/12/2022] [Indexed: 12/23/2022] Open
Abstract
Patients with cholangiocarcinoma (CCA) often have an unfavorable prognosis because of its insidious nature, low resectability rate, and poor response to anticancer drugs and radiotherapy, which makes early detection and treatment difficult. At present, CCA has a five-year overall survival rate (OS) of only 5%, despite advances in therapies. New an increasing number of evidence suggests that nanoplatforms may play a crucial role in enhancing the pharmacological effects and in reducing both short- and long-term side effects of cancer treatment. This document reviews the advantages and shortcomings of nanoparticles such as liposomes, polymeric nanoparticle,inorganic nanoparticle, nano-metals and nano-alloys, carbon dots, nano-micelles, dendrimer, nano-capsule, bio-Nanomaterials in the diagnosis and treatment of CCA and discuss the current challenges in of nanoplatforms for CCA.
Collapse
Affiliation(s)
- Chunkang Liu
- Department of Gastrointestinal Surgery, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Kunzhe Wu
- Department of Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Jianyang Li
- Department of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Xupeng Mu
- Department of Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Huan Gao
- Department of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Xiaohua Xu
- Department of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, China.
| |
Collapse
|
3
|
Cecilia JA, Moreno-Tost R. Recent Advances in Mesoporous Materials and Their Biomedical Applications. Int J Mol Sci 2022; 23:ijms232415636. [PMID: 36555279 PMCID: PMC9779131 DOI: 10.3390/ijms232415636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Accepted: 12/05/2022] [Indexed: 12/14/2022] Open
Abstract
Since the beginning of civilization, porous materials have been used for medical purposes [...].
Collapse
|
4
|
López-Ruiz M, Navas F, Fernández-García P, Martínez-Erro S, Fuentes MV, Giráldez I, Ceballos L, Ferrer-Luque CM, Ruiz-Linares M, Morales V, Sanz R, García-Muñoz RA. L-arginine-containing mesoporous silica nanoparticles embedded in dental adhesive (Arg@MSN@DAdh) for targeting cariogenic bacteria. J Nanobiotechnology 2022; 20:502. [PMID: 36457046 PMCID: PMC9714087 DOI: 10.1186/s12951-022-01714-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Accepted: 11/16/2022] [Indexed: 12/03/2022] Open
Abstract
Dental caries is the major biofilm-mediated oral disease in the world. The main treatment to restore caries lesions consists of the use of adhesive resin composites due to their good properties. However, the progressive degradation of the adhesive in the medium term makes possible the proliferation of cariogenic bacteria allowing secondary caries to emerge. In this study, a dental adhesive incorporating a drug delivery system based on L-arginine-containing mesoporous silica nanoparticles (MSNs) was used to release this essential amino acid as a source of basicity to neutralize the harmful acidic conditions that mediate the development of dental secondary caries. The in vitro and bacterial culture experiments proved that L-arginine was released in a sustained way from MSNs and diffused out from the dental adhesive, effectively contributing to the reduction of the bacterial strains Streptococcus mutans and Lactobacillus casei. Furthermore, the mechanical and bonding properties of the dental adhesive did not change significantly after the incorporation of L-arginine-containing MSNs. These results are yielding glimmers of promise for the cost-effective prevention of secondary caries.
Collapse
Affiliation(s)
- Marta López-Ruiz
- grid.28479.300000 0001 2206 5938Faculty of Health Sciences, IDIBO Research Group, Rey Juan Carlos University, Madrid, Spain
| | - Francisco Navas
- grid.28479.300000 0001 2206 5938Department of Chemical and Environmental Technology, Rey Juan Carlos University, C/ Tulipán S/N Móstoles, 28933 Madrid, Spain
| | - Paloma Fernández-García
- grid.28479.300000 0001 2206 5938Department of Chemical and Environmental Technology, Rey Juan Carlos University, C/ Tulipán S/N Móstoles, 28933 Madrid, Spain
| | - Samuel Martínez-Erro
- grid.28479.300000 0001 2206 5938Department of Chemical and Environmental Technology, Rey Juan Carlos University, C/ Tulipán S/N Móstoles, 28933 Madrid, Spain
| | - Mª Victoria Fuentes
- grid.28479.300000 0001 2206 5938Faculty of Health Sciences, IDIBO Research Group, Rey Juan Carlos University, Madrid, Spain
| | - Isabel Giráldez
- grid.28479.300000 0001 2206 5938Faculty of Health Sciences, IDIBO Research Group, Rey Juan Carlos University, Madrid, Spain
| | - Laura Ceballos
- grid.28479.300000 0001 2206 5938Faculty of Health Sciences, IDIBO Research Group, Rey Juan Carlos University, Madrid, Spain
| | - Carmen Mª Ferrer-Luque
- grid.4489.10000000121678994Department of Stomatology, School of Dentistry, University of Granada, Campus de Cartuja, Colegio Máximo S/N, 18071 Granada, Spain
| | - Matilde Ruiz-Linares
- grid.4489.10000000121678994Department of Stomatology, School of Dentistry, University of Granada, Campus de Cartuja, Colegio Máximo S/N, 18071 Granada, Spain
| | - Victoria Morales
- grid.28479.300000 0001 2206 5938Department of Chemical and Environmental Technology, Rey Juan Carlos University, C/ Tulipán S/N Móstoles, 28933 Madrid, Spain
| | - Raúl Sanz
- grid.28479.300000 0001 2206 5938Department of Chemical and Environmental Technology, Rey Juan Carlos University, C/ Tulipán S/N Móstoles, 28933 Madrid, Spain
| | - Rafael A. García-Muñoz
- grid.28479.300000 0001 2206 5938Department of Chemical and Environmental Technology, Rey Juan Carlos University, C/ Tulipán S/N Móstoles, 28933 Madrid, Spain
| |
Collapse
|
5
|
Dual (pH- and ROS-) Responsive Antibacterial MXene-Based Nanocarrier for Drug Delivery. Int J Mol Sci 2022; 23:ijms232314925. [PMID: 36499252 PMCID: PMC9739462 DOI: 10.3390/ijms232314925] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 11/19/2022] [Accepted: 11/24/2022] [Indexed: 12/02/2022] Open
Abstract
In this study, a novel MXene (Ti3C2Tx)-based nanocarrier was developed for drug delivery. MXene nanosheets were functionalized with 3, 3'-diselanediyldipropionic acid (DSeDPA), followed by grafting doxorubicin (DOX) as a model drug to the surface of functionalized MXene nanosheets (MXene-Se-DOX). The nanosheets were characterized using scanning electron microscopy, atomic force microscopy (AFM), transmission electron microscopy, energy-dispersive X-ray spectroscopy (EDX), nuclear magnetic resonance spectroscopy, Fourier transform infrared spectroscopy, X-ray photoelectron spectroscopy, X-ray diffraction, and zeta potential techniques. The drug-loading capacity (17.95%) and encapsulation efficiency (41.66%) were determined using ultraviolet-visible spectroscopy. The lateral size and thickness of the MXene nanosheets measured using AFM were 200 nm and 1.5 nm, respectively. The drug release behavior of the MXene-Se-DOX nanosheets was evaluated under different medium conditions, and the nanosheets demonstrated outstanding dual (reactive oxygen species (ROS)- and pH-) responsive properties. Furthermore, the MXene-Se-DOX nanosheets exhibited excellent antibacterial activity against both Gram-negative E. coli and Gram-positive B. subtilis.
Collapse
|
6
|
Kankala RK, Han YH, Xia HY, Wang SB, Chen AZ. Nanoarchitectured prototypes of mesoporous silica nanoparticles for innovative biomedical applications. J Nanobiotechnology 2022; 20:126. [PMID: 35279150 PMCID: PMC8917689 DOI: 10.1186/s12951-022-01315-x] [Citation(s) in RCA: 33] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 02/17/2022] [Indexed: 02/06/2023] Open
Abstract
Despite exceptional morphological and physicochemical attributes, mesoporous silica nanoparticles (MSNs) are often employed as carriers or vectors. Moreover, these conventional MSNs often suffer from various limitations in biomedicine, such as reduced drug encapsulation efficacy, deprived compatibility, and poor degradability, resulting in poor therapeutic outcomes. To address these limitations, several modifications have been corroborated to fabricating hierarchically-engineered MSNs in terms of tuning the pore sizes, modifying the surfaces, and engineering of siliceous networks. Interestingly, the further advancements of engineered MSNs lead to the generation of highly complex and nature-mimicking structures, such as Janus-type, multi-podal, and flower-like architectures, as well as streamlined tadpole-like nanomotors. In this review, we present explicit discussions relevant to these advanced hierarchical architectures in different fields of biomedicine, including drug delivery, bioimaging, tissue engineering, and miscellaneous applications, such as photoluminescence, artificial enzymes, peptide enrichment, DNA detection, and biosensing, among others. Initially, we give a brief overview of diverse, innovative stimuli-responsive (pH, light, ultrasound, and thermos)- and targeted drug delivery strategies, along with discussions on recent advancements in cancer immune therapy and applicability of advanced MSNs in other ailments related to cardiac, vascular, and nervous systems, as well as diabetes. Then, we provide initiatives taken so far in clinical translation of various silica-based materials and their scope towards clinical translation. Finally, we summarize the review with interesting perspectives on lessons learned in exploring the biomedical applications of advanced MSNs and further requirements to be explored.
Collapse
|